Join us for the 2024 Avis Distinguished Visiting Professorship lecture featuring David Z. D’Argenio, PhD, on October 11 at noon in the College of Pharmacy Building 102.
About David Z. D’Argenio, PhD
David Z. D’Argenio, PhD, is Professor of Biomedical Engineering at the Viterbi School of Engineering of the University of Southern California and the inaugural holder of the Chonette Chair of Biomedical Technology. He is also an Adjunct Professor in the Department of Pharmaceutical Sciences at the University at Buffalo, SUNY. Dr. D’Argenio has been a member of the Biomedical Engineering Faculty at USC since 1979. He is a Fellow of the American Institute for Engineering in Medicine and Biology, the American Association of Pharmaceutical Scientists, and the International Society of Pharmacometrics. From 2003-2008 he served on the US FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology. He has served as Chairman of the Department of Biomedical Engineering at USC from 1996-2003 and was the inaugural holder of the Dwight C. and Hildagarde E. Baum Chair of Biomedical Engineering. He also served as the Associate Dean for Academic Affairs in the School of Engineering at USC from 1993-1996 and as the Interim Director of the Alfred Mann Institute of BME at USC from 1998-1999. Dr. D’Argenio has been a visiting scientist at St. Jude Children’s Research Hospital, Memphis and at the Institute of Biomedical Engineering, CNR, Padova, Italy, as well as a visiting professor at the University of Halle-Wittenberg, Halle, Germany.
His awards include the Lewis B. Sheiner Award from the International Society of Pharmacometrics in 2018; the Gerhard Levy Distinguished Lectureship, Univ. of Buffalo, SUNY, 2016; the Mellon Mentoring Award, Univ. Southern California, 2010; the USC School of Engineering Service Award, 1992; the USC School of Engineering and TRW Excellence in Teaching Award in 1985. He was a co-founder of the International Society of Pharmacometrics (2010). Professor D’Argenio has served as a consultant for numerous pharmaceutical and biotechnology companies and was a founding member of the Board of Directors of Simulations Plus (NASDAQ: SLP), Inc. from 1996-2016.